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Abstract
Large hour-to-hour variability has previously been demonstrated in the cerebrospinal fluid (CSF) concentrations of Alzheimer’s disease
(AD) biomarkers amyloid 42 (A42) and A40 in healthy younger subjects. We investigated the within-subject variability over 36 hours
in CSF A and tau proteins, in older subjects and AD patients. Six patients with mild stage AD (59–85 years, Mini Mental State
Examination (MMSE) 16–26) and 6 healthy older volunteers (64–77 years) received an intrathecal catheter from which, during 36 hours,
each hour 6 mL of CSF was drawn. Concentrations of A42, A40, total tau, and phosphorylated tau were determined and the variability
as analyzed. Within-subject variability within 3-hour periods was assessed as the coefficient of variation, which was comparable for these
biomarkers in controls (4.2%–4.6%) and AD (3.1%–5.8%). Variability over 12 hour periods was 5.3% to 9.5%. These findings suggest
hat CSF biomarker variability is relatively low in healthy older controls and AD patients. Furthermore, continuous sampling of CSF proved
o be a useful and robust method, which may also be used to investigate AD pathogenesis and to evaluate pharmacotherapeutic interventions.
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h1. Introduction
Cerebrospinal fluid (CSF) biomarker analysis has proven
to be a useful additional tool in Alzheimer’s disease (AD)
diagnostics (Bibl et al., 2006; Blennow et al., 2010; Dubois
et al., 2007; Le Bastard et al., 2010; Paraskevas et al., 2009).
However, between-subject and between-laboratory variabil-
* Corresponding author at: Department of Geriatric Medicine, Radboud
University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen,
The Netherlands. Tel.: 31 24 361 6772; fax: 31 24 361 7408.sE-mail address: j.claassen@ger.umcn.nl (J.A.H.R. Claassen).
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Open access under the Elsevier OA license.ity hinders the definition of clear-cutoff values for clinical
practice across different institutes (de Jong et al., 2006;
Lewczuk et al., 2006; Sunderland et al., 2003; Verwey et al.,
2009). Whether within-subject variability also adds to these
uncertainties remains unclear.
Although concentrations of CSF amyloid  protein
(A) and tau proteins were stable in longitudinally col-
ected samples over a period of months (Andersson et al.,
008; Blennow et al., 2007; Kanai et al., 1998), important
ariability, a 1.5- to 4-fold difference between lowest and
ighest values of A40 and A42, was demonstrated in a
tudy performing hourly CSF sampling with an intrathe-
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831.e2 D. Slats et al. / Neurobiology of Aging 33 (2012) 831.e1–831.e9cal catheter over 12 to 36 hours (Bateman et al., 2007).
Moreover, the pattern of variability suggested a circadian
rhythm. This method of continuous CSF sampling may be
of major value in studying both the pathophysiology of
AD-related CSF biomarkers and the acute effects of fu-
ture therapies on these biomarkers, but further explor-
ative studies are needed. Until now, these data were
obtained in mostly young healthy volunteers (10 out of
15 volunteers were younger than 45 years) and, therefore,
this method of continuous CSF sampling should be ex-
tended to older subjects and patients with AD, in order to
determine daily variability in the relevant age groups.
Moreover, the within-subject variability of other AD bio-
markers, i.e., total tau (t-tau) and phosphorylated tau
(p-tau), have not been studied.
We hypothesized that AD patients and healthy older
control subjects display within-subject (circadian) variabil-
ity of CSF biomarkers. We further hypothesized that the
magnitude and pattern of variability might be influenced by
AD pathology and therefore differ between patients and
controls. In the present study, we realized a safe and inno-
vative methodology to longitudinally monitor and analyze
the within-subject variability of CSF A40, A42, t-tau, and
-tau levels up to 36 hours in AD patients and healthy older
ontrol subjects.
. Methods
.1. Subjects
AD patients were recruited at the memory clinic of
adboud University Nijmegen Medical Centre (RUNMC).
Table 1
Demographics and CSF biomarker characteristics of AD patients and hea
AD patients
1 2 3
ge, y 77 67 69
ender M F M
umber of samples 36 36 36
42
Mean 136 87 79
Range 41–178 41–126 41–99
40
Mean 9164 8296 7975
Range 1730–11,910 895–11,235 3130–10
-tau
Mean 149 499 291
Range 67–241 307–667 200–39
-tau
Mean 52 141 115
Range 40–62 126–155 88–15
42, t-tau, and p-tau were analyzed with an xMAP-based Innobia assay (
mmunosorbent assay (ELISA). In the first 3 hours a lag phase was detected
s mean, with range (minimum–maximum), in pg/mL.
ey:  41, below detection range; A, amyloid  protein; AD, Alzheim
rylated tau; t-tau, total tau.
* Significant differences between mean biomarker concentrations in ADhey were diagnosed with “probable AD” in accordance withhe National Institute of Neurological and Communicative Dis-
rders and Stroke and the Alzheimer’s Disease and Related
isorders Association (NINCDS-ADRDA) criteria (McKhann
t al., 1984). After careful assessment all AD patients were
ound competent to consent (Meulenbroek et al., 2010). The
ontrol group consisted of healthy older individuals over 50
ears of age, recruited from the population using advertise-
ents in local newspapers. Their cognitive status was ex-
mined using the Mini Mental State Examination (MMSE)
nd individuals with scores below 28 were excluded. All
articipants gave written consent to participate in the study.
hey underwent a thorough clinical investigation to ensure
ood clinical health and absence of neurological disease
ther than AD. This included medical history, physical,
eurological, and psychiatric examination, and screening
aboratory tests of blood and electrocardiogram (ECG). Six
atients with AD and 6 healthy older control subjects were
ncluded in this study. There were no differences between
he groups regarding gender, age (Table 1), or any of the
outine laboratory tests (data not shown). The median Mini
ental State Examination score in the AD group was 23
range 16–26), compared with 30 (range 29–30; p 0.002)
n the control group.
.2. Study protocol
Participants were admitted to a specially designed
esearch room on the evening of Day 1 to check general
ealth, vital signs, and draw blood for laboratory tests.
etween 8:00 and 9:00 AM on Day 1 an intrathecal cath-
ter was placed, and from 10:00 AM hourly CSF samples
were collected. After 36 hours of sampling the intrathecal
er volunteers over 36 hours
4 5 6 All
71 64 75 71
M F F 3:3
29 36 36
137 102 124 110
70–171 43–126 41–174 41–178
8014 6509 10576 8447
3125–9675 2075–8745 550–12,960 550–12,960
249 162 212 263*
195–324 77–215 142–284 67–667
96 77 84 95*
70–121 54–97 54–111 40–155
netics NV, Ghent, Belgium) and A40 was analyzed using enzyme-linked
2 and A40, which was not excluded in these results. All data are expressed
ease; CSF, cerebrospinal fluid; F, female; M, male; p-tau, hyperphospho-
ntrol group; p  0.05.lthy old
,365
7
1
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hospital. On day 7 participants returned to the hospital for
a check-up visit. On day 30 participants were contacted
by phone and checked for any adverse events. During the
36-hour measurement period a research nurse was always
present, assisting the participants and continuously mon-
itoring for adverse events. Motion and sleep were regis-
tered every hour and meal times were standardized.
Sleeping times, though, were not standardized and before
each CSF collection participants were briefly awoken to
ensure safe collection. All procedures and analyses were
performed according to the latest guidelines on Good
Clinical Practice and Good Laboratory Practice.
2.3. Placement of intrathecal catheter
The indwelling intrathecal catheter, a Perifix Softtip
Catheter G20/88 mm with Perifix epidural filter 0.2 m
Braun Melsungen AG, Melsungen, Germany), was placed
nder local anesthesia and aseptic conditions in an operation
oom by an experienced anesthesiologist (Hahn et al.,
002). A lumbar puncture was performed, using the L3-4
nterspace, with a bore 18 gauge Tuohy needle. The catheter
ip was advanced 10 cm into the intrathecal space. The
atheter was connected to a covered bacterial filter. A loop
as made in the catheter to relieve tension, and the catheter
as taped over the participant’s shoulder. The catheter was
emoved by the study physician immediately after the last
ample had been taken. Subjects were observed for 12 hours
fter removal to ensure proper sealing of the cannula inser-
ion point. There were no complications at the placement
nd after the removal of the spinal catheter.
.4. CSF analyses
Every hour 6 mL of CSF was collected in polypropylene
ubes, resulting in 36 samples. In 1 AD patient the final 7 of
he 36 samples are missing due to accidental removal of the
Table I
Continued
Control group
7 8 9 10
85 64 67
F F
36 36 36
178 96 169
41–290 41–160 41–276 4
4,024 10,409 6882 10
725–17,205 1038–13,095 657–8180 6
153 176 163
35–173 127–255 118–204
46 72 68
6–68 51–87 56–79atheter, and in 1 control subject 2 nightly samples were notollected, according to the subject’s preference. All samples
ere immediately transported to the adjacent laboratory and
entrifuged at 2000g for 5 minutes to eliminate cells and
ther insoluble material. All CSF samples contained clear
uid and, upon visual inspection, did not contain blood.
hese procedures are in line with current international
uidelines (Blennow et al., 1993). Aliquots were stored
t 80 °C within 30 minutes after withdrawal until bio-
hemical analysis (Schoonenboom et al., 2005).
CSF A42, t-tau, and p-tau were determined using the
MAP-based Innobia assay (Innogenetics NV, Ghent, Bel-
ium) and CSF A40 was determined using enzyme-linked
immunosorbent assay (ELISA) (The Genetics Company,
Schlieren, Switzerland) according to the manufacturer’s
specifications. For validation of the results, CSF A42, t-tau,
nd p-tau analyses were repeated at Merck Research labo-
atories (Kenilworth, NJ, USA) using the xMAP-based In-
obia assay (Innogenetics NV), and CSF A42 and A40
were also repeated using an MSD multiplex assay (Me-
soscale Diagnostics, Gaithersburg, MD, USA) (Supplemen-
tary Table 1). Total protein levels in CSF were analyzed
using the Lowry method. All samples were analyzed in
duplicate (except for total protein) and, to minimize inter-
assay variation, all samples from a single participant were
measured in the same plate and all samples were analyzed
using identical production batch numbers. The analytical
coefficients of variation (CV) for CSF analyses in this study,
which were assessed by including the same sample in dif-
ferent analytical runs, were 11.8% for A40, 10.2% for
A42, 9.3% for t-tau, and 8.3% for p-tau.
2.5. Statistical analyses
Descriptive statistics of all biomarkers concentrations
over 36 hours were determined, both for individuals and by
group. A lag phase was identified in the first hourly mea-
surements (see Results) and to correct for this the first 3
11 12 All
83 59 71
M F 3:3
36 34
124 352 202
41–140 90–519 41–519
7475 7152 9424
15 1860–11,190 2185–9285 657–17,205
101 84 124*
74–123 69–107 47–255
67 28 52*
56–83 24–34 20–8763
M
36
299
1–393
,425
85–12,9
64
47–88
28samples in all subjects were excluded from further statistical
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lated in both groups. To investigate within-subject hour-to-
hour fluctuations for shorter time periods, the CVs for bio-
marker measurements were also calculated for time periods
of 3 and 12 hours using a mixed linear model with subject,
time period (3- and 12-hour) and their interaction as fixed
factors. The dependent variable was the logarithm of the
concentrations. This resulted in an estimate of the pooled
standard deviation of the logarithms of the concentrations
measured within 3- or 12-hour periods, and after back-
transformation in an estimate of the CV. Of note, on the
logarithmic scale, 95% of the measurements differed by less
than 4 standard deviations from each other. Therefore, we
can state that 95% of the concentrations that were measured
within a period of 3 or 12 hours varied less than approxi-
mately 4 times the CV. In this sense, this CV represents an
indication for the precision of the measurements.
Time trends in the biomarker levels were analyzed by
means of a linear mixed model with subject as random
factor. To account for the longitudinal relationship of sam-
ples a first-order autoregressive covariance structure was
used. In order to remove heteroscedasticity, all biomarker
values were first log transformed. The results of the analyses
were back-transformed and are presented as percentages. To
investigate the presence of circadian patterns we included a
cosinar analysis in the model (first order Fourier analysis).
Fig. 1. Hourly fluctuations of cerebrospinal fluid (CSF) biomarkers over 3
presented in pg/mL, were analyzed from hourly CSF samples of a single re
myloid  protein; AD, Alzheimer’s disease; p-tau, hyperphosphorylatedAll analyses were performed using SPSS 16.0 (IBM, Ar- mmonk, NY, USA) and graphs were constructed using Sig-
maplot 10.0 (Systat Software Inc, San Jose, CA, USA).
3. Results
Individual and group means of CSF A40, A42, t-tau,
and p-tau for AD and controls are shown in Table 1. A40
and A42 concentrations were lower in AD than in control,
lthough this did not reach statistical significance, while
ean t-tau (p  0.03) and p-tau (p  0.02) were signifi-
antly higher. Two healthy control subjects had low A42
levels, which, in 1 of these subjects, was also accompanied
by a high t-tau and a slightly elevated p-tau.
In all subjects, in the first hours of sampling a lag phase was
detected in A40 and A42, but not in t-tau and p-tau concen-
rations, with values far below the 36-hour average. An exam-
le of this lag phase is depicted in a typical curve of 1 AD
atient in Fig. 1A and B; CSF biomarker curves of all subjects
re provided in Supplementary Fig. 1. We performed an in
itro experiment to determine the cause of this lag phase.
hrough 2 catheters, 1 with and 1 without a bacterial filter
ttached, 8 CSF samples of 6 mL were drawn. The results
emonstrated that the presence of the bacterial filter was re-
ponsible for an artificial reduction in A42 concentration of
early 100% in the initial samples (Fig. 2A). Therefore, to
nvestigate whether the bacterial filter could affect the assess-
in a single AD patient. A40 (A), A42 (B), t-tau (C), and p-tau (D), all
ative AD patient. The first sample was taken at 10 AM. Abbreviations: A,
u, total tau.6 hours
presentent of variability, in a second experiment we tested how this
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concentrations (Fig. 2B–D). Eight 6-mL aliquots were drawn
alternately from 2 CSF pools, 1 with high and 1 with low
concentrations of A42, t-tau, and p-tau. Results demonstrated
hat the bacterial filter did not substantially attenuate the dif-
erences between these high and low concentrations. More
recisely, t-tau and p-tau concentrations were not altered,
nd high A42 concentrations were underestimated by
% while low A42 concentrations were overestimated
y 4%. Variability between the high and low concentra-
ion A42 pools ( 200%) was underestimated by 16%
due to the filter.
Hour-to-hour variability of absolute CSF A40, A42,
t-tau, and p-tau concentrations over 36 hours is shown in
Fig. 3. This graph illustrates significant within-subject
variability, but also large between-subject as well as
between-group variability. Variability can be expressed
by the CV over 33 (36 minus lag phase) hours (Table 2).
CVs in the AD group were 10.9% for A40, 11.1% for
A42, 18.7% for t-tau, and 13.4% for p-tau. In the control
roup CVs were 11.2% for A40, 14.4% for A42, 11.4% for
t-tau, and 11.5% for p-tau. This analysis, however, is con-
founded by between-subject variability, as well as by the
strong temporal relationship of repeated measurements.
To account for this, we first analyzed time trends in these
data by means of a linear mixed model. In AD patients, but
Fig. 2. Two in vitro experiments investigating the influence of the bac
6-mL aliquots of a CSF pool were drawn through 2 catheters, either w
time intervals. A reference sample was drawn directly from the CSF
MAP-based Innobia assay (Innogenetics NV, Ghent, Belgium). (B, C a
lternately from 2 CSF pools, 1 with high and 1 with low concentratio
as created by addition of synthetic A42 to the pool, whereas the other
from both CSF pools (dotted lines). All samples were analyzed in du
numbers, uneven sample numbers are from the high concentration CS
amyloid  protein; p-tau, hyperphosphorylated tau; t-tau, total tau.not in controls, a significant linear trend in t-tau was ob-served with an increase of 1.1% per hour (p  0.001). The
same linear trend was observed in p-tau in AD, with an
increase of 1.0% per hour (p  0.001).
We then explored circadian patterns in these biomarkers
using a cosinar fit, which revealed a significant circadian
fluctuation pattern in A40, with an amplitude of 517 pg/mL
for the AD group and 358 pg/mL for the control group (p 
0.001); in A42, with an amplitude of 7.5 pg/mL for the AD
roup and 15.5 pg/mL for the control group (p  0.005);
nd in p-tau, with an amplitude of 2.5 pg/mL for the AD
roup and 1.4 for the control group (p 0.01). No circadian
attern was seen for t-tau in either group.
Next, we calculated the CVs for the repeated biomarker
easurements within 3- and 12-hour periods throughout the 33
ours using mixed linear model analysis. For measurements
ithin 3 hours, these CVs were in AD 3.4% for A40, 3.1% for
42, 4.7% for t-tau, and 5.8% for p-tau. In controls, these
CVs were 4.6% for A40, 4.6% for A42, 4.2% for t-tau, and
.5% for p-tau, which was not significantly different from the
D group. For measurements within 12-hour periods these
Vs were in AD 5.5% for A40, 5.7% for A42, 9.5% for
t-tau, and 7.7% for p-tau. In controls, these CVs were 5.4% for
A40, 6.7% for A42, 5.4% for t-tau, and 5.3% for p-tau. To
aid the interpretation of these 3- and 12-hour CV’s, as dis-
cussed in the statistical methods section, these results imply
that any 2 measurements taken within a 3- or 12-hour period
lter on cerebrospinal fluid (CSF) biomarkers measurements. (A) Eight
n circles) or without (closed circles) a bacterial filter, at the indicated
otted line). All samples were analyzed for A42 in duplicate with an
ight 6-mL aliquots were drawn through a catheter with a bacterial filter,
42, t-tau, and p-tau. The high concentration of A42 in the CSF pool
ool was used without additives. Reference samples were directly drawn
with an xMAP-based Innobia assay. Horizontal axes present sample
, even numbers from the low concentration pool. Abbreviations: A,terial fi
ith (ope
pool (d
nd D) E
ns of A
CSF p
plicate
F poolwill not differ by more than 20%.
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The method of hourly CSF sampling successfully mea-
sured variability of AD biomarkers in both healthy older
controls and AD patients, extending previously published
results of this method in young volunteers (Bateman et al.,
2007). The main findings are that, overall, A variability
was smaller than in these younger subjects, with low CV’s
for samples taken 3 and 12 hours apart, and significant
Fig. 3. Mean hourly fluctuations of cerebrospinal fluid (CSF) biomarkers
of CSF biomarkers A40 (A), A42 (B), t-tau (C), and p-tau (D) were calcu
D group results are shown in closed circles, the healthy older volunteer gr
isease; A, amyloid  protein; p-tau, hyperphosphorylated tau; t-tau, tot
able 2
SF biomarker characteristics and coefficients of variation over 33 hours
Biomarker Analysis AD patients
Mean Range
42 Luminex (RUNMC) 114 64–178
Luminex (Merck) 142 77–254
MSD 896 375–124
40 ELISA 8798 4800–12,9
MSD 10,328 4594–13,4
t-tau Luminex (RUNMC) 268 67–667
Luminex (Merck) 500 178–106
p-tau Luminex (RUNMC) 96 40–155
Luminex (Merck) 109 47–190
or validation A42, t-tau, and p-tau were analyzed in duplo, with a Lu
aboratory in RUMCN in the Netherlands and at Merck Research Labor
Schlieren, Switzerland) and both A42 and A40 were also analyzed using
ere excluded. The within-subject variability for each group was calculated
s mean, with range (minimum–maximum), in pg/mL.
ey: A, amyloid  protein; AD, Alzheimer’s disease; CSF, cerebrospin
adboud University Nijmegen Medical Centre; t-tau, total tau.circadian patterns. For the first time, variability in tau pro-
teins is reported, demonstrating an as yet unexplained linear
increase (baseline drift) over 36 hours.
Within-subject CVs of samples taken 1–3 or 1–12 hours
apart was between 3.1% and 9.5% for CSF A40, A42,
-tau, and p-tau in AD patients and healthy older control
ubjects, with no significant difference in variability be-
ween both groups. This variability was lower than expected
hours in AD patients and healthy older volunteers. Mean concentrations
r hour for both groups. The first 3 hours were excluded, due to a lag phase.
pen squares, 95% confidence interval. Abbreviations: AD, Alzheimer’s
patients and healthy older controls
Control group
CV (%) Mean Range CV (%)
11.1 210 83–519 14.4
13.3 242 115–812 11.8
10.7 1371 540–2456 12.3
10.9 9788 4380–17,205 11.2
11.4 11,416 5617–17,311 10.5
18.7 124 47–255 11.4
14.5 230 70–418 10.8
13.4 52 20–87 11.5
12.6 73 24–158 14.8
xMAP-based Innobia assay (Innogenetics NV, Ghent, Belgium) at the
(NJ, USA). A40 was analyzed using ELISA (The Genetics Company,
D multiplex assay (Mesoscale Diagnostics, MD, USA). The first 3 hours
coefficient of variation, separately for each analysis. All data are expressed
; CV, coefficient of variation; p-tau, hyperphosphorylated tau; RUNMC,over 33
lated pe
oup in oof AD
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831.e7D. Slats et al. / Neurobiology of Aging 33 (2012) 831.e1–831.e9from previous work in younger subjects, which reported
large hour-to-hour fluctuations in CSF biomarkers, based on
visual assessment and calculation of the ratio between the
maximum and minimum values over 9, 12, or 36 hours
(Bateman et al., 2007). These ratios (2.5 for A1-x, 3.1 for
A40, and 3.3 for A42) were higher than ratios we calcu-
ated for comparison over 36 hours from our own data; in
he AD group 1.7 for A40, 1.7 for A42, 2.4 for t-tau, and
1.7 for p-tau, and in the control group 1.7 for A40, 1.4 for
42, 1.6 for t-tau, and 1.6 for p-tau. We will discuss 4
possible explanations for this difference in variability be-
tween the studies.
First, the difference may be partly explained by the lag
phase that was observed for A, but not for tau, in all
ubjects. We contemplated that this is an artifact due to the
acterial filter, which was confirmed using an in vitro ex-
eriment in our laboratory. That experiment demonstrated a
ag phase in A42 concentration when CSF was drawn
through a catheter with filter, and the absence of such a lag
phase when the filter was left out. A peptides are known to
stick to the walls of test tubes made of glass or polystyrene,
and therefore polypropylene test tubes are recommended
(Vanderstichele et al., 1998). A peptides probably also
stick to the filter material, which induces a lag phase, until
the filter is saturated and measurements become represen-
tative. The lag phase resulted in inaccurately low A values
in the first few samples, which would have overestimated
the 36-hour variability. Therefore these first samples were
excluded from our analysis. A similar lag phase can be
identified in the study with younger subjects (Bateman et
al., 2007) and thus may have augmented variability, how-
ever that study did not use the bacterial filter (Bateman,
personal communication).
Second, adding to the first in vitro experiment which
showed that CSF concentrations were stable after the lag
phase, our second in vitro experiment investigated how
alternate sampling of CSF samples with high and low bio-
marker concentrations would be affected by the “sticky”
bacterial filter. This experiment showed that the filter had a
small effect on A42, but not t-tau or p-tau. Likely, satura-
tion of the bacterial filter with A42 is a dynamic process
uring which new A peptides bind to the material when
CSF with a high concentration is drawn and are released
when CSF with a lower concentration is drawn. This “flat-
tening effect” on A concentrations however only resulted
in modest underestimation of the in vitro variability from
200% to 184%. Nonetheless, future studies using this design
of continuous CSF sampling should avoid using a filter, to
ensure representative variability.
Third, we used mixed modeling as a statistical method to
assess CVs for the CSF biomarkers. With this method we
are able to correct for between-subject variability, which is
high for all biomarkers investigated here, but also to correct
for temporal trends that we identified in our study, which
can be artificially induced by the methodology of continu- Fous sampling. However, also the unprocessed CVs and the
ratios between maximum and minimum values yield lower
variability in our dataset than in the previously described
study (Bateman et al., 2007).
The fourth and most salient explanation for the differ-
ence in variability between these studies is that the pres-
ent work investigated older subjects and older AD pa-
tients, suggesting that CSF biomarker variability is
reduced with aging and AD. Indeed, in the study with
younger subjects a circadian pattern was observed, based
on peaks and troughs that were recognized in the aver-
aged 36-hour recordings of CSF A (Bateman et al.,
007). Using cosinar analysis, we were also able to detect
statistically significant circadian pattern in CSF A42
nd A40. However, the amplitudes of these changes
were much smaller, with the peak-trough difference rang-
ing from 3.8% to 7.7%. Our study was not designed to
account for circadian influences such as sleep; moreover
the study environment, including nightly sampling, will
have affected normal circadian physiology, therefore,
further study is needed to explore the nature and cause of
circadian variability in A. As the mechanisms behind
SF A variability remain unknown, we can only spec-
ulate why variability is reduced in aging and AD. Fluc-
tuations in the rate of neuronal production or clearance of
A may underlie short-term and circadian variability.
owever, thus far, studies that have addressed A pro-
uction and clearance rates, estimated by administering
table isotope-labeled amino acids, found no evidence for
our-to-hour variability. In 1 study early steady state
evels of A were observed over a period of 15 hours
(Bateman et al., 2006), while in another study hour-to-
hour changes in production of A before and during
administration of a -secretase-inhibitor showed no cir-
adian pattern in A production (Bateman et al., 2009).
 production and clearance rates, and possible changes
erein, should be further characterized, as well as the
nfluence of circadian rhythms on these factors. At the
ame time other possible causes for hourly variability of
SF biomarkers should be identified.
A linear increase in t-tau and p-tau concentrations over
6 hours was seen in the AD group, but not in the control
roup. Such a linear trend suggested a methodological
rtifact, likely to be caused by the catheter in vivo. This
s the first study in which hourly t-tau and p-tau concen-
rations were described. However, previous studies have
hown that these biomarkers remain stable over longer
eriods of time, when CSF is sampled longitudinally via
umbar punctures (Andreasen et al., 1999; Blennow et al.,
007; Zetterberg et al., 2007). Therefore, we hypothesize
hat the increase seen here is a result of the substantial
rainage of CSF in this study; a hypothesis that is sup-
orted by a concomitant rise in CSF total protein ob-
erved in AD but not in control subjects (Supplementary
ig. 2). Apparently, healthy volunteers can compensate
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patients cannot. CSF production can be decreased in AD
patients (Silverberg et al., 2001). The cause of this de-
crease may be found in pathological changes of the cho-
roid plexus, such as epithelial atrophy, basement mem-
brane thickening, and amyloid deposition in choroidal
blood vessels (Serot et al., 2000; Silverberg et al., 2003).
The steady and gradual increase of CSF total protein, and
the fact that this was only observed in AD patients,
argues against neuronal damage provoked by insertion of
the intrathecal catheter. We speculate that the reduction
in CSF volume, induced by repeated sampling, may have
led to a larger than normal transfer of tau proteins from
interstitial fluid (possibly containing higher concentra-
tions of t-tau and p-tau) to CSF, resulting in a progress-
ive rise in CSF t-tau and p-tau. Why A concentrations
re not affected in the same way as t-tau and p-tau by the
eduction in CSF volume remains unclear. Perhaps this is
ue to the fact that this protein is actively cleared and that
ts clearance across the blood-brain barrier is still effi-
ient. However, in a previous study it was shown that A
concentrations increased up to 200% of baseline over 36
hours (Bateman et al., 2009). This difference remains
unexplained. Whatever may be the cause, it is important
to realize that repeated CSF sampling, especially if a
large total volume is withdrawn in a short period of time,
apparently alters normal physiology and may thus con-
found results. This is of relevance for the design and
interpretation of future studies that use repeated CSF
sampling.
In conclusion, short-term biological within-subject vari-
ability of CSF A and tau concentrations was lower than
expected, including a much less pronounced circadian pat-
tern compared with earlier observations in younger subjects.
For a practical implication, these results indicate that the
time of day for a single diagnostic lumbar puncture in
clinical practice does not have to be standardized. However,
our results require independent confirmation in more sub-
jects and in experiments with the use of catheters without
bacterial filters. Furthermore, unraveling the mechanisms
behind both the rapid fluctuations in biomarkers and their
reduced variability in aging and AD, may yield important
advances in our understanding of the pathogenesis of spo-
radic AD. Moreover, the observed differences in circadian
rhythm of A may hold information about its physiology
nd perhaps better understanding of the factors that influ-
nce A concentrations may pave new ways toward treat-
ent. Finally, these results demonstrate that, after fine-
uning of the method, this technique of repeated CSF
ampling with a spinal catheter proves a very promising
ool, not only for the study of Alzheimer pathophysiology,
ut also for monitoring of drug treatments in intervention
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